دورية أكاديمية
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
| العنوان: | Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias. |
|---|---|
| المؤلفون: | Barroso SDS; Northeast Biotechnology Network Post-Graduating, Tiradentes University, Aracaju, Brazil.; Laboratory of Morphology and Experimental Pathology, Research and Technology Institute, Aracaju, Brazil., Lopes LES; Laboratory of Morphology and Experimental Pathology, Research and Technology Institute, Aracaju, Brazil.; Health and Environment Post-Graduating Program, Tiradentes University, Aracaju, Brazil., Santos KS; Laboratory of Morphology and Experimental Pathology, Research and Technology Institute, Aracaju, Brazil., Gomes MZ; Northeast Biotechnology Network Post-Graduating, Tiradentes University, Aracaju, Brazil.; Laboratory of Morphology and Experimental Pathology, Research and Technology Institute, Aracaju, Brazil.; Health and Environment Post-Graduating Program, Tiradentes University, Aracaju, Brazil. |
| المصدر: | Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2019 Dec; Vol. 29 (12), pp. 979-985. Date of Electronic Publication: 2019 Nov 13. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 9516419 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7674 (Electronic) Linking ISSN: 13543776 NLM ISO Abbreviation: Expert Opin Ther Pat Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: London : Ashley Pub. Ltd., c1994- |
| مواضيع طبية MeSH: | Antiparkinson Agents/*adverse effects , Dyskinesia, Drug-Induced/*drug therapy , Levodopa/*adverse effects, Animals ; Antiparkinson Agents/administration & dosage ; Disease Models, Animal ; Dopamine/metabolism ; Humans ; Levodopa/administration & dosage ; Parkinson Disease/drug therapy ; Patents as Topic |
| مستخلص: | Introduction : Parkinson's disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (DA) depletion in the striatum. Dopamine replacement therapies with the 3,4-dihydroxy-L-phenylalanine (Levodopa or L-DOPA) represent the most common strategy to treat PD. However, chronic administration of L-DOPA results in abnormal involuntary movement (AIMs). Thus, the present study aimed to prospect patents of alternative treatment strategies for L-DOPA-induced dyskinesias. Areas covered : This review covers the therapeutic patents published over the 2001-2019 period in the WIPO, INPI, and ESPACENET, which report treatment strategies for L-DOPA induced dyskinesias (LIDs). Expert opinion : In recent years, several pharmaceutical companies, as well as universities and researchers have tested effective compounds for LIDs treatment, showing substances that act on central pathways as antagonists and agonists of the serotonergic system, which may result in the key to onset of LIDs in animal models of PD. Future works aiming to elucidate the L-DOPA, Flibanserin, Eltoprazine, and Pridopidina mechanisms of action on the receptors of the serotonergic system and D |
| فهرسة مساهمة: | Keywords: Patents; abnormal involuntary movement; dyskinesias; technological prospection |
| المشرفين على المادة: | 0 (Antiparkinson Agents) 46627O600J (Levodopa) VTD58H1Z2X (Dopamine) |
| تواريخ الأحداث: | Date Created: 20191108 Date Completed: 20191225 Latest Revision: 20191225 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1080/13543776.2019.1690453 |
| PMID: | 31694421 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7674 |
|---|---|
| DOI: | 10.1080/13543776.2019.1690453 |